The structure of raloxifene
Find information on thousands of medical conditions and prescription drugs.

Evista

Raloxifene is an oral selective estrogen receptor modulator which is used in the prevention of osteoporosis in postmenopausal women. There has been some evidence that raloxifene can reduce the incidence of breast cancer, but this has yet to be proven in a clinical setting. Raloxifene is produced by Eli Lilly Pharmaceuticals and is sold under the brand name Evista.

SERMs mimic estrogen in some tissues and have anti-estrogen activity in others. Other SERMs, such as Pfizer's lasofoxifene and Wyeth's bazedoxifene are in the late stages of clinical development.

Home
Diseases
Medicines
A
B
C
D
E
E-Base
Ecstasy (drug)
Edecrin
Edrophonium
Edrophonium chloride
Efavirenz
Effexor
Eflornithine
Elavil
Eldepryl
Elidel
Eligard
Elitek
Elixomin
Elixophyllin
Ellagic acid
Elmiron
Eloxatin
Elspar
Emtriva
Emylcamate
Enalapril
Enalaprilat
Enalaprilat
Endep
Enflurane
Enoxaparin sodium
Entacapone
Enulose
Epi-pen
Epinephrine
Epirubicin
Epitol
Epivir
Epogen
Eprosartan
Ergocalciferol
Ergoloid Mesylates
Ergotamine
Eryc
Eryped
Erythromycin
Esgic
Eskalith
Esmolol
Estazolam
Estazolam
Estrace
Estraderm
Estradiol
Estradiol
Estradiol valerate
Estring
Estrogel
Estrone
Estrostep
Ethacridine
Ethambutol
Ethchlorvynol
Ethosuximide
Ethotoin
Etiracetam
Etodolac
Etopophos
Etoposide
Etorphine
Evista
Exelon
Exemestane
Hexal Australia
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Raloxifene reduces the risk of breast cancer
From American Family Physician, 4/1/05 by Henry Barry

Clinical Question: does raloxifene prevent breast cancer?

Setting: Outpatient (any)

Study Design: Randomized controlled trial (double-blinded)

Allocation: Uncertain

Synopsis: This study, the Continuing Outcomes Relevant to Evista (CORE) trial, is a continuation of the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. Researchers in the MORE trial found that raloxifene decreased the incidence of invasive breast cancer among postmenopausal women with osteoporosis (number needed to treat [NNT] = 93 for four years; 95 percent confidence interval [CI], 61 to 161; [Cauley JA, et al. Continued breast cancer reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial (published correction appears in Breast Cancer Res Treat May 2001;67:191). Breast Cancer Res Treat January 2001;65:125-34]). This study was designed to assess the longer term safety and efficacy of raloxifene.

Of the 6,511 patients in the MORE trial, 4,011 chose to continue in the CORE trial. This drop off between the two studies may have introduced bias in favor of the treatment group. In the CORE trial, the researchers did not re- randomize patients; they continued the same allocation (1,286 took placebo, and 2,725 took raloxifene) and maintained the double blinding of the original trial. To be eligible, women had to be 80 years or younger, have osteoporosis by bone density measurement, and be at least two years beyond menopause. Finally, the researchers evaluated the outcomes by intention to treat.

During the four years of the CORE trial, significantly more patients taking placebo developed breast cancer (2.3 versus 1.1 per-cent of patients taking raloxifene; NNT = 84; 95 percent CI, 45 to 282). No significant differences occurred in total mortality, total adverse events, serious adverse events, or drug discontinuations. However, pulmo-nary emboli increased significantly when all eight years of data were combined (adjusted risk ratio = 0.46 percent; NNT to harm = 214; 95 percent CI, 117 to 10,000).

Bottom Line: Previous research has shown that raloxifene can protect against breast can-cer after four years of use. In this four-year extension of the original study, this level of protection continued. (Level of Evidence: 1b)

Study Reference: Martino S, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst December 1, 2004;96:1751-61.

Used with permission from Barry H. Raloxifene reduces breast cancer risk (CORE). Accessed online January 25, 2005, at: http://www.InfoPOEMs.com.

COPYRIGHT 2005 American Academy of Family Physicians
COPYRIGHT 2005 Gale Group

Return to Evista
Home Contact Resources Exchange Links ebay